AAVogen

AAVogen is a private, preclinical-stage biotech focused on creating safer, more effective AAV-based gene therapies for muscle disorders. Its core technology involves muscle-tropic AAV vectors engineered to avoid the toxicities seen in other gene therapies, aiming to durably increase muscle mass and strength. The pipeline features AVGN7 for IBM, heart failure, and sarcopenic obesity, and a combination therapy (AVGN7+AVGND) for DMD. Founded by a family personally affected by muscle wasting diseases, the company operates with a lean, virtual model, leveraging key external partners for research, manufacturing, and regulatory strategy.

Proprietary muscle-tropic adeno-associated virus (AAV) vectors engineered for targeted delivery to skeletal and cardiac muscle, designed to minimize systemic toxicity. The lead vector delivers the Smad7 gene to inhibit the myostatin/activin signaling pathway, promoting muscle growth and preventing atrophy.

In DMD, AAVogen faces competition from approved micro-dystrophin gene therapies (e.g., Sarepta's ELEVIDYS) and other modalities. In muscle wasting, companies like Scholar Rock (targeting myostatin/activin with antibodies) and Biohaven (taldefgrobep alfa) represent competitive, non-gene therapy approaches. AAVogen's differentiation lies in its muscle-specific gene therapy designed for durable, localized expression of an intracellular inhibitor (Smad7).